Amgen Inc.

Shu-Chen Lu

Jerry Ryan Holder

Shanaka Stanislaus

Bin Wu

Yuan Cheng

Leslie Phillip Miranda

James Richard Falsey

Murielle M Veniant-Ellison

Bradley J Herberich

Junming Yie

Chawita Netirojjanakul

Minghan Wang

Jing M Xu

Kelvin C Sham

David J Lloyd

Jing Xu

Kelvin Sham

Murielle M Venient-Ellison

Method of treating metabolic diseases and disorders using a composition comprising a GLP-V/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)

This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.

Methods of treating retinal disorders with anti-apelin antibodies

Apelin antigen-binding proteins and uses thereof

Growing community of inventors

Thousand Oaks, CA, United States of America

Shu-Chen Lu